While Q220 is down in history as a disastrous quarter, marred by the dark mark of COVID-19, Q320 is the bright ray of sunshine companies in the US Joint Fluid Replacement market had hoped for.
For Q320, HA companies shared upbeat notes about renewed product demand, fueled by an uptick in activity from patients (out and about), distribution channels, and physicians treating an influx of new, as well as existing patients. One of the factors benefiting the HA market is the backlog of patients awaiting their turn for knee arthroplasty (TKA) and remain in need of treatment to manage their knee osteoarthritis (KOA) pain.
Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 US Joint Fluid Market Recap* are:
- Complete Market Overview and Highlights
- US Joint Fluid Segment Recap
- Leading Company Recap
- Notable Developments in Q320
- Looking Ahead
Although Q320 finished on a positive note and was what the companies had hoped for to make up for lost revenue, there is still strong uncertainty about how the year will end. Going into Q420, the number of new COVID-19 cases started to increase at an alarming rate, prompting several states to reinstate stronger travel and social distancing measures. With COVID-19 continuing to be a dark cloud over the US Joint Fluid Replacement market, companies remain hesitant to ...
*The entire article, including revenue, shares and links can only be viewed by SmartTRAK subscribers to this module.
To see all the new and exciting offerings coming to SmartTRAK in 2021, or to request more info about what SmartTRAK can do for you, just click the button below.